Table 2.
Serum vastatin in CRC samples and relationship with clinico-pathological parameters.
| Variable | Serum vastatin, ng/ml, median (range) | p-value | |
|---|---|---|---|
| Tumor location | Colon | 6.46 (1.88–17.43) | 0.183 |
| Rectum | 3.83 (3.02–37.41) | ||
| Tumor stage | Stage 1 | 5.77 (3.20–37.41) | 0.885 |
| Stage 2 | 7.28 (1.88–17.39) | ||
| Stage 3 | 5.66 (3.02–17.43) | ||
| Stage 4 | 6.46 (3.83–11.37) | ||
| Tumor stage | Stage 1 + 2 | 6.41 (1.88–37.41) | 0.702 |
| Stage 3 + 4 | 5.66 (3.02–17.43) | ||
| TNM class T | T1+ T2 | 6.28 (3.20–37.41) | 0.919 |
| T3+ T4 | 6.03 (1.88–17.43) | ||
| TNM class N | N0 | 5.9 (1.88–37.41) | 0.990 |
| N1 + 2 | 6.46 (3.02–17.43) | ||
| TNM class M | M0 | 6.03 (1.88–37.41) | 0.803 |
| M1 | 6.46 (3.83–11.37) | ||
| VI | V0 | 6.79 (1.88–37.41) | 0.489 |
| V1 | 5.38 (2.43–17.43) | ||
CRC: colorectal cancer; TNM: T: tumor, N: node, M: metastasis; VI: venous invasion